Advanced Solid Tumor Clinical Trials & Research at St. Joseph Health
Medical Group
St. Joseph Health Medical Group is currently enrolling patients for the
following advanced solid tumor clinical trials:
A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability,
and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12)
in Subjects with Locally Advanced, Unresectable, or Metastatic Solid Tumors
(EMD 0031)
Treatment agent: Avelumab + NHS-IL12 (interleukin-12 Ab conjugate)
PI:
Thomas Stanton, MD
Study Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links:
clinicaltrials.gov NCT No: NCT02994953
eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects
Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient
Response to Checkpoint Inhibitor Alone (eFFECTOR)
Treatment agent: eFT508 + PD-1/PD-L1 Inhibitor Therapy
PI:
Thomas Stanton, MD
Study Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links:
clinicaltrials.gov NCT No: NCT03616834
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability,
and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors (Hutchison)
Treatment agent: Fruquintinib
PI:
Thomas Stanton, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT03251378
SEERPRO: A Prospective Blood Sample Collection Study to Evaluate a Panel
of Protein-based Biomarkers (SEER)
Treatment agent:
Single-visit blood sample collection
PI:
Thomas Stanton, MD
Study Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: Not available
A Multi- Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal
and Breast Cancer
Treatment: Fruquintinib
PI:
Ian Anderson, MD
Coordinator: Kayla
Resources and Links:
clinicaltrials.gov NCT No: NCT03251378
Efficacy and Safety of Pemigatinib in Previously treated locally advanced/metastatic
or Surgically unresectable solid tumor malignancies harboring activating
FGFG Mutations or Translocations(FIGHT-207)
Treatment: Pemigatinib
PI:
Ian Anderson, MD
Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT0363184
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected
Gastrointestinal and Genitourinary Tumors
Treatment: Ibrutinib, Everolimus, Docetaxel, Paclitaxel, Cetuximab, Pembrolizumab
PI:
Wes Lee, MD
Coordinator: Teresa
Resources and Links:
clinicaltrials.gov NCT No: NCT02599324
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Treatment: ladiratuzumab vedotin
PI:
Ian Anderson, MD
Coordinator: Diego
Resources and Links:
clinicaltrials.gov NCT No: NCT04032704
Seer-020102
PI:
Manasa Vulchi, MD
Coordinator: Camille
A Study of Repotrectinib(TPX-0005) in Patients With Advanced Solid Tumors
Harboring ALK, ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
Treatment: Oral Repotrectinib
PI:
Ian Anderson, MD
Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT03093116